Joann V Pinkerton

Summary

Affiliation: University of Virginia
Country: USA

Publications

  1. ncbi request reprint Estrogen and cognition, with a focus on Alzheimer's disease
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, University of Virginia Health System, Midlife Health Center, 2955 Ivy Road Suite 104, Charlottesville, VA 22903, USA
    Semin Reprod Med 23:172-9. 2005
  2. ncbi request reprint Use of SERMs for treatment in postmenopausal women
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, Division of Midlife Health, University of Virginia Health System, Charlottesville, VA, United States Electronic address
    J Steroid Biochem Mol Biol 142:142-54. 2014
  3. ncbi request reprint Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, Division of Midlife Health Center, University of Virginia Health System, Charlottesville, VA 22903, USA
    Obstet Gynecol 121:959-68. 2013
  4. doi request reprint Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial
    Joann V Pinkerton
    University of Virginia Health System, Charlottesville 22903, USA
    Menopause 20:38-46. 2013
  5. doi request reprint Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial
    Joann V Pinkerton
    University of Virginia Health System, Charlottesville, VA 22903, USA
    Menopause 20:28-37. 2013
  6. doi request reprint Endometrial safety: a key hurdle for selective estrogen receptor modulators in development
    Joann V Pinkerton
    University of Virginia, Charlottesville, VA, USA
    Menopause 17:642-53. 2010
  7. pmc Menstrual cycle-related exacerbation of disease
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, University of Virginia, PO Box 801104, Northridge Ste 104, Charlottesville, VA 22908, USA
    Am J Obstet Gynecol 202:221-31. 2010
  8. doi request reprint Treatment of postmenopausal osteoporosis in a patient with celiac disease
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, Division of Midlife Health, University of Virginia Health System, 2955 Ivy Road, Suite 104, PO Box 801104, Charlottesville, VA 22908, USA
    Nat Rev Endocrinol 6:167-71. 2010
  9. doi request reprint Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis
    Joann V Pinkerton
    University of Virginia, Charlottesville, VA 22908, USA
    Menopause 16:1102-8. 2009
  10. doi request reprint Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial
    Joann V Pinkerton
    University of Virginia, Midlife Health Center and Division, Charlottesville, VA 22903, USA
    Menopause 16:1116-24. 2009

Detail Information

Publications37

  1. ncbi request reprint Estrogen and cognition, with a focus on Alzheimer's disease
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, University of Virginia Health System, Midlife Health Center, 2955 Ivy Road Suite 104, Charlottesville, VA 22903, USA
    Semin Reprod Med 23:172-9. 2005
    ....
  2. ncbi request reprint Use of SERMs for treatment in postmenopausal women
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, Division of Midlife Health, University of Virginia Health System, Charlottesville, VA, United States Electronic address
    J Steroid Biochem Mol Biol 142:142-54. 2014
    ..This article is part of a Special Issue entitled 'Menopause'. ..
  3. ncbi request reprint Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, Division of Midlife Health Center, University of Virginia Health System, Charlottesville, VA 22903, USA
    Obstet Gynecol 121:959-68. 2013
    ....
  4. doi request reprint Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial
    Joann V Pinkerton
    University of Virginia Health System, Charlottesville 22903, USA
    Menopause 20:38-46. 2013
    ....
  5. doi request reprint Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial
    Joann V Pinkerton
    University of Virginia Health System, Charlottesville, VA 22903, USA
    Menopause 20:28-37. 2013
    ....
  6. doi request reprint Endometrial safety: a key hurdle for selective estrogen receptor modulators in development
    Joann V Pinkerton
    University of Virginia, Charlottesville, VA, USA
    Menopause 17:642-53. 2010
    ..Further investigation of newer SERMs is warranted to more clearly define the endometrial safety of these agents...
  7. pmc Menstrual cycle-related exacerbation of disease
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, University of Virginia, PO Box 801104, Northridge Ste 104, Charlottesville, VA 22908, USA
    Am J Obstet Gynecol 202:221-31. 2010
    ..Hormones may be helpful...
  8. doi request reprint Treatment of postmenopausal osteoporosis in a patient with celiac disease
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, Division of Midlife Health, University of Virginia Health System, 2955 Ivy Road, Suite 104, PO Box 801104, Charlottesville, VA 22908, USA
    Nat Rev Endocrinol 6:167-71. 2010
    ..A 62-year-old postmenopausal woman with a family history of breast cancer, mild gastroesophageal reflux disease, iron-deficient anemia and declining BMD was seen in a specialist center for the evaluation and management of osteoporosis...
  9. doi request reprint Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis
    Joann V Pinkerton
    University of Virginia, Charlottesville, VA 22908, USA
    Menopause 16:1102-8. 2009
    ..The aim of this study was to examine the endometrial, ovarian, and breast safety of bazedoxifene, a novel selective estrogen-receptor modulator, in postmenopausal women at risk for osteoporosis...
  10. doi request reprint Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial
    Joann V Pinkerton
    University of Virginia, Midlife Health Center and Division, Charlottesville, VA 22903, USA
    Menopause 16:1116-24. 2009
    ..The aim of this study was to assess the safety and efficacy of bazedoxifene (BZA)/conjugated estrogens (CE) treating moderate to severe vasomotor symptoms in the Selective Estrogen Menopause and Response to Therapy 2 trial...
  11. doi request reprint Reproductive aging, menopause, and health outcomes
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, Divisions of Midlife, University of Virginia Health System, Charlottesville, Virginia 22908, USA
    Ann N Y Acad Sci 1204:169-78. 2010
    ....
  12. doi request reprint Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women
    Joann V Pinkerton
    University of Virginia Health System, Division of Midlife, Department of Obstetrics and Gynecology, Box 801104, Charlottesville, VA 22908, USA
    Expert Opin Investig Drugs 19:1613-21. 2010
    ....
  13. ncbi request reprint Combination therapy for treatment of osteoporosis: A review
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, Midlife Health, University of Virginia Health System, Charlottesville, VA 22908, USA
    Am J Obstet Gynecol 197:559-65. 2007
    ..Although combination therapy, in general, has limitations based on cost, concern about potential oversuppression of bone, and lack of long-term safety and fracture efficacy, selected patients may benefit...
  14. doi request reprint Pharmacological therapy for abnormal uterine bleeding
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, Division of Midlife Health, University of Virginia Health System, Charlottesville, VA 22908, USA
    Menopause 18:453-61. 2011
    ..Emergency use of parenteral conjugated estrogens has a 70% chance of stopping abnormal bleeding but an increased risk of thrombosis...
  15. ncbi request reprint Vasomotor symptoms in menopause: where we've been and where we're going
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, Division of Midlife Health, University of Virginia Health System, Charlottesville, 22908, USA
    J Womens Health (Larchmt) 15:135-45. 2006
    ..Agreement about the definition of menopause and its associated symptoms is critically important for the design and evaluation of new therapies and for the optimal treatment of women during this important phase of their lives...
  16. doi request reprint Advances in the treatment of menopausal symptoms
    Joann V Pinkerton
    University of Virginia Health System, Charlottesville, VA 22908, USA
    Womens Health (Lond Engl) 5:361-384; quiz 383-4. 2009
    ....
  17. doi request reprint Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials
    Joann V Pinkerton
    1 Department of Obstetrics and Gynecology, Division of Midlife Health, University of Virginia Health System, Charlottesville, Virginia
    J Womens Health (Larchmt) 23:18-28. 2014
    ..Secondary outcomes from these trials were evaluated to determine whether the effects of BZA/CE are influenced by years since menopause (YSM)...
  18. ncbi request reprint Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, Division of Midlife Health J V P and Department of Radiology J A H, University of Virginia Health System, Charlottesville, Virginia 22908 Department of Medicine R L, Helen Hayes Hospital, West Haverstraw, New York 10993 Women s Health K P, A A C, S M, Pfizer Inc, Collegeville, Pennsylvania 19426 and Department of Obstetrics and Gynecology D F A, Clinical Research Center, Eastern Virginia Medical School, Norfolk, Virginia 23510
    J Clin Endocrinol Metab 99:E189-98. 2014
    ..This phase 3 study evaluated the endometrial safety of bazedoxifene (BZA)/conjugated estrogens (CE) and bone mineral density (BMD) effects vs BZA alone, hormone therapy, and placebo (PBO)...
  19. ncbi request reprint Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens
    Jennifer A Harvey
    Department of Radiology, University of Virginia Health System, Charlottesville, VA 22908, USA
    Menopause 20:138-45. 2013
    ..Breast density is associated with an increased risk of breast cancer. This study assessed changes in mammographic breast density after 24 months of treatment with bazedoxifene (BZA)/conjugated estrogens (CE) in postmenopausal women...
  20. doi request reprint Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial
    Joann V Pinkerton
    From the 1Division of Midlife Health Center, Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, VA 2Pfizer Inc, Collegeville, PA and 3Pfizer Ltd, Tadworth, Surrey, UK
    Menopause 21:252-9. 2014
    ....
  21. ncbi request reprint Estrogen agonists/antagonists in combination with estrogen for prevention and treatment of menopause-associated signs and symptoms
    Dale W Stovall
    The University of Virginia School of Medicine, Department of Obstetrics and Gynecology, UVA Northridge, Suite 304, 2955 Ivy Road, Charlottesville, VA 22903, USA
    Womens Health (Lond Engl) 4:257-68. 2008
    ....
  22. doi request reprint Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms
    Dale W Stovall
    Department of Obstetrics and Gynecology, Divisions of Reproductive Endocrinology and Midlife Health, University of Virginia Health System, Charlottesville, USA
    Drugs 71:1649-57. 2011
    ..Data regarding the effects of combination conjugated estrogens/bazedoxifene therapy on bone are promising in terms of the prevention and treatment of post-menopausal osteoporosis...
  23. doi request reprint Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling
    Joann V Pinkerton
    From the 1Division of Midlife Health, Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, VA 2Pfizer Inc, Groton, CT and 3Pfizer Inc, Collegeville, PA
    Menopause 21:243-51. 2014
    ....
  24. ncbi request reprint MF-101, an estrogen receptor beta agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women
    Dale W Stovall
    The University of Virginia Health System, Department of Obstetrics and Gynecology, Divisions of Reproductive Endocrinology and Midlife Health, Box 801104, Charlottesville, VA 22903, USA
    Curr Opin Investig Drugs 10:365-71. 2009
    ..If these isolates were demonstrated to be as effective and safe in clinical trials as preliminary data suggest regarding MF-101, these compounds could change the way clinicians treat menopause-associated symptoms...
  25. ncbi request reprint Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women
    Joann V Pinkerton
    University of Virginia Health System, Charlottesville, VA, USA
    Menopause 10:45-52. 2003
    ..To determine the potential interaction of oral raloxifene 60 mg/day on the efficacy of a low-dose, estradiol-releasing vaginal ring used to treat signs and symptoms of vaginal atrophy in postmenopausal women...
  26. ncbi request reprint Osteoporosis treatment and prevention for postmenopausal women: current and future therapeutic options
    Joann V Pinkerton
    Department of Obstetrics and Gynecology, Division of Midlife Health Center Department of Medicine, Division of Endocrinology and Metabolism, University of Virginia Health System, Charlottesville, Virginia
    Clin Obstet Gynecol 56:711-21. 2013
    ..Bazedoxifene with conjugated estrogens, novel delivery of teriparatide, new parathyroid hormone proteins, anti-sclerostin antibodies, cathepsin K inhibitors, and stem cell therapies are in testing. ..
  27. ncbi request reprint Gamete retrieval in terminal conditions: is it practical? What are the consequences?
    James J Finnerty
    Department of Obstetrics and Gynecology, University of Virginia Health Sciences Center, Box 800726, Charlottesville, VA 22908, USA
    Curr Womens Health Rep 2:174-8. 2002
    ..A policy was developed and approved by the Ethics Committee at our institution, and is included in this article...
  28. ncbi request reprint Treatment of urogenital atrophy with low-dose estradiol: preliminary results
    Richard J Santen
    Department of Medicine, Division of Endocrinology, University of Virginia Health Sciences Center, Charlottesville 22908, USA
    Menopause 9:179-87. 2002
    ..To determine the lowest dosage of vaginally administered estradiol (E2) that reverses signs and symptoms of urogenital atrophy but does not substantially increase plasma E2 levels...
  29. ncbi request reprint An expert offers advice on the use of unregulated, custom-compounded hormones
    Joann V Pinkerton
    University of Virginia Health Sciences Center, Charlottesville, VA, USA
    Geriatrics 63:1 p following 20. 2008
  30. ncbi request reprint End-of-life discussions for the primary care obstetrician/gynecologist
    James F Finnerty
    Department of Obstetrics and Gynecology, University of Virginia Medical Center, Charlottesville, 22908, USA
    Am J Obstet Gynecol 187:296-301. 2002
    ..End-of-life decisions are much more stressful when surrogate decision makers do not know in advance what decisions a patient would want made if the patient becomes incapacitated...
  31. ncbi request reprint Reproduction in couples who are affected by human immunodeficiency virus: medical, ethical, and legal considerations
    Christopher D Williams
    Department of Obstetrics and Gynecology, University of Virginia School of Medicine, Charlottesville, VA 22903, USA
    Am J Obstet Gynecol 189:333-41. 2003
    ....
  32. ncbi request reprint Postmenopausal hormone therapy: an Endocrine Society scientific statement
    Richard J Santen
    Division of Endocrinology and Metabolism, University of Virginia, Charlottesville, Virginia 22908, USA
    J Clin Endocrinol Metab 95:s1-s66. 2010
    ..No funding was provided to any expert or peer reviewer, and all participants volunteered their time to prepare this Scientific Statement...
  33. ncbi request reprint Cervical cancer and human papillomavirus in indigenous Guyanese women
    Rebecca S Kightlinger
    Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA, USA
    Am J Obstet Gynecol 202:626.e1-7. 2010
    ..The purpose of this study was to determine the prevalence of cervical disease, human papillomavirus infection, and human papillomavirus (HPV) genotypes in indigenous villages of Guyana...
  34. ncbi request reprint Acceptance of fragile X premutation genetic screening in women with ovarian dysfunction
    Lisa M Pastore
    Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA 22908 0712, USA
    Am J Obstet Gynecol 194:738-43. 2006
    ..The purpose of this study was to assess patient perception of fragile X premutation genetic testing (FRAX)...
  35. ncbi request reprint Perspective on menopausal vasomotor symptoms, CAM, and the SWAN
    Joann V Pinkerton
    Menopause 14:601-5. 2007
  36. ncbi request reprint The effects of abuse on health problems in menopausal women
    Joann V Pinkerton
    Menopause 15:1-4. 2008
  37. pmc Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society
    Wulf H Utian
    Menopause 15:584-602. 2008
    ....